Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of AM-111 in acute sensorineural hearing loss
2008-000132-40Phase 2Completed
- Sponsor
- Altamira Therapeutics
- Start
- Sep 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in sensorineural hearing loss (SNHL) comparing AM-111 intratympanic injection with Placebo intratympanic injection (2 arms). Primary endpoint: Absolute improvement in pure tone audiometry (PTA) at day 7. Started Sep 2008; status: completed.
02
Drugs
brimapitide
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on 2008-000132-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000132-40.